More Early Stocks in Motion

Tenet walks past estimates. InterMune's lung-drug trial is successful.
Author:
Publish date:

Tenet Healthcare

(THC) - Get Report

said its first-quarter loss narrowed from a year ago despite slightly lower revenue, beating estimates. The hospital operator lost $3 million, or 1 cent a share, in the quarter, compared with a loss of $122 million, or 26 cents a share, last year. On a continuing basis, earnings were 1 cent a share, about 6 cents better than analysts expected.

Given Imaging

(GIVN)

said it earned $1.2 million, or 4 cents a share, for the first quarter ended March 31, compared to a loss of $585,000 or 2 cents a share, a year ago. Revenue for the quarter was $22 million. According to Thomson First Call, analysts expected earnings of 4 cents a share on sales of $22.5 million. For the second quarter, the company expects profits of 6 cents to 10 cents a share on revenue in the range of $22 million to $24 million. Analysts were expecting profits of 11 cents a share on sales of $24.4 million, according to Thomson First Call. The stock was down $2, or 7.14%, to $26 in afterhours trading.

Corning

(GLW) - Get Report

said it expects second-quarter pro-forma earnings of 17 cents to 19 cents a share on revenue in the range of $1.08 billion to $1.13 billion. Analysts were expecting earnings of 18 cents a share on revenue of $1.1 billion. The stock was down a penny, to $13.80, in afterhours trading.

Cutera

(CUTR) - Get Report

said it earned $1.5 million, or 11 cents a share, for the first quarter ended March 31, compared to $221,000, or 2 cents a share, a year ago. Revenue for the quarter was $15.1 million. Analysts expected earnings of 7 cents a share on revenue of $14.6 million. The stock was up 78 cents, or 4.38%, to $18.60 in afterhours trading.

InterMune

(ITMN)

said its experimental drug pirfenidone was so successful in treatment for a fatal lung disorder that its planned 12-month phase II trial was stopped after nine months. The drug is designed for the treatment of pulmonary fibrosis. The stock was up 57 cents, or 5.39%, to $11.15 in afterhours trading.